# First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

> **NCT03231722** · PHASE3 · COMPLETED · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 435 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** l-leucovorin
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT03231722
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-13
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-24
- **Target enrollment:** 435 (ACTUAL)
- **Last updated:** 2023-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03231722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03231722, "First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03231722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*